JP2019531745A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531745A5 JP2019531745A5 JP2019520801A JP2019520801A JP2019531745A5 JP 2019531745 A5 JP2019531745 A5 JP 2019531745A5 JP 2019520801 A JP2019520801 A JP 2019520801A JP 2019520801 A JP2019520801 A JP 2019520801A JP 2019531745 A5 JP2019531745 A5 JP 2019531745A5
- Authority
- JP
- Japan
- Prior art keywords
- cmv
- mir
- vector
- nucleic acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701022 Cytomegalovirus Species 0.000 claims 34
- 239000013598 vector Substances 0.000 claims 30
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 12
- 150000007523 nucleic acids Chemical group 0.000 claims 12
- 108091008874 T cell receptors Proteins 0.000 claims 8
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 108700011259 MicroRNAs Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 239000002679 microRNA Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 108091023084 miR-126 stem-loop Proteins 0.000 claims 3
- 108091065272 miR-126-1 stem-loop Proteins 0.000 claims 3
- 108091081187 miR-126-2 stem-loop Proteins 0.000 claims 3
- 108091030790 miR-126-3 stem-loop Proteins 0.000 claims 3
- 108091092317 miR-126-4 stem-loop Proteins 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- 101150088910 UL82 gene Proteins 0.000 claims 2
- 101150085955 US11 gene Proteins 0.000 claims 2
- 210000003038 endothelium Anatomy 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- -1 miR-130a Proteins 0.000 claims 2
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims 2
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 108010083359 Antigen Receptors Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108091008875 B cell receptors Proteins 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000021309 Germ cell tumor Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 206010061598 Immunodeficiency Diseases 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- 108091028080 MiR-132 Proteins 0.000 claims 1
- 108091033773 MiR-155 Proteins 0.000 claims 1
- 108091036422 MiR-296 Proteins 0.000 claims 1
- 108091028049 Mir-221 microRNA Proteins 0.000 claims 1
- 108091062140 Mir-223 Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 241001631646 Papillomaviridae Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 101150016730 UL79 gene Proteins 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000007813 immunodeficiency Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 108091064282 miR-125 stem-loop Proteins 0.000 claims 1
- 108091037066 miR-125-1 stem-loop Proteins 0.000 claims 1
- 108091062107 miR-125-2 stem-loop Proteins 0.000 claims 1
- 108091079767 miR-125-3 stem-loop Proteins 0.000 claims 1
- 108091032320 miR-146 stem-loop Proteins 0.000 claims 1
- 108091024530 miR-146a stem-loop Proteins 0.000 claims 1
- 108091062762 miR-21 stem-loop Proteins 0.000 claims 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 claims 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 claims 1
- 108091048308 miR-210 stem-loop Proteins 0.000 claims 1
- 108091061917 miR-221 stem-loop Proteins 0.000 claims 1
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims 1
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims 1
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims 1
- 108091029997 miR-328 stem-loop Proteins 0.000 claims 1
- 108091027983 miR-378-1 stem-loop Proteins 0.000 claims 1
- 108091089716 miR-378-2 stem-loop Proteins 0.000 claims 1
- 108091050734 miR-652 stem-loop Proteins 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169043A JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409840P | 2016-10-18 | 2016-10-18 | |
| US62/409,840 | 2016-10-18 | ||
| PCT/US2017/057106 WO2018075591A1 (en) | 2016-10-18 | 2017-10-18 | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169043A Division JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019531745A JP2019531745A (ja) | 2019-11-07 |
| JP2019531745A5 true JP2019531745A5 (enExample) | 2020-11-26 |
Family
ID=62018862
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520801A Pending JP2019531745A (ja) | 2016-10-18 | 2017-10-18 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター |
| JP2022169043A Active JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169043A Active JP7478794B2 (ja) | 2016-10-18 | 2022-10-21 | 主要組織適合遺伝子複合体ｅ分子によって拘束されるｔ細胞を誘発するサイトメガロウイルスベクター及びｈｃｍｖベクターを含む組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10532099B2 (enExample) |
| EP (1) | EP3529363B1 (enExample) |
| JP (2) | JP2019531745A (enExample) |
| KR (1) | KR102604486B1 (enExample) |
| CN (1) | CN110036112B (enExample) |
| AU (1) | AU2017346788A1 (enExample) |
| BR (1) | BR112019007982A2 (enExample) |
| CA (1) | CA3040303A1 (enExample) |
| CL (1) | CL2019001054A1 (enExample) |
| CO (1) | CO2019004102A2 (enExample) |
| CR (1) | CR20190205A (enExample) |
| DO (1) | DOP2019000086A (enExample) |
| EA (1) | EA201990937A1 (enExample) |
| EC (1) | ECSP19031754A (enExample) |
| IL (1) | IL266011B2 (enExample) |
| MA (1) | MA46588A (enExample) |
| MX (1) | MX2019004518A (enExample) |
| PE (1) | PE20190840A1 (enExample) |
| SG (1) | SG11201903340TA (enExample) |
| TN (1) | TN2019000124A1 (enExample) |
| UA (1) | UA126860C2 (enExample) |
| WO (1) | WO2018075591A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3333265T1 (sl) | 2010-05-14 | 2020-08-31 | Oregon Health & Science University | Rekombinantni HCMV in RHCMV vektorji, ki kodirajo heterologni antigen izoliran iz virusa hepatitisa B virus in njihove uporabe |
| LT2691530T (lt) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glikoproteinai ir rekombinantiniai vektoriai |
| HRP20181930T1 (hr) | 2013-03-05 | 2019-01-11 | Oregon Health & Science University | Citomegalovirus vektori za kontroliranje ciljanja t-stanica |
| CN107002048B (zh) | 2014-07-16 | 2021-07-06 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| CA2976245A1 (en) | 2015-02-10 | 2016-08-18 | Oregon Health & Science University | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| MX2019004518A (es) | 2016-10-18 | 2019-06-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e. |
| US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| CN114025792A (zh) * | 2019-03-21 | 2022-02-08 | 21C生物公司 | 针对感染期间的致病性免疫激活细胞的疫苗 |
| CN113950334B (zh) * | 2019-06-07 | 2025-01-28 | 俄勒冈健康与科学大学 | 乙型肝炎病毒特异性t细胞应答 |
| US20220257740A1 (en) * | 2019-06-07 | 2022-08-18 | Oregon Health & Science University | Tumor-associated antigen-specific t cell responses |
| MY210519A (en) * | 2019-08-20 | 2025-09-29 | Univ Oregon Health & Science | Modulation of t cell responses by ul18 of human cytomegalovirus |
| WO2021045969A1 (en) | 2019-08-29 | 2021-03-11 | Vir Biotechnology, Inc. | Hepatitis b virus vaccines |
| EP4076510A4 (en) * | 2019-12-16 | 2024-01-10 | Oregon Health & Science University | MULTI-SPECIFIC T CELL RECEPTORS |
| US20240384296A1 (en) | 2021-08-31 | 2024-11-21 | Vir Biotechnology, Inc. | Recombinant hcmv vectors and uses thereof |
| IL310667A (en) | 2021-08-31 | 2024-04-01 | Vir Biotechnology Inc | Tuberculosis vaccines |
| EP4630027A1 (en) | 2022-12-09 | 2025-10-15 | DYS-Immune Therapeutics | Composite aids vaccine generating anti-hiv specific neutralizing antibodies and/or anti-hiv cytotoxic t cells |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| ATE118822T1 (de) | 1987-06-26 | 1995-03-15 | Syntro Corp | Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung. |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| EP1092775A1 (en) | 1991-07-05 | 2001-04-18 | American Cyanamid Company | Methods for identifiying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegalovirus |
| AU7192394A (en) | 1993-07-19 | 1995-02-20 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| DE69535125T2 (de) | 1994-04-29 | 2007-08-30 | Pharmacia & Upjohn Co. Llc, Kalamazoo | Impfstoff gegen felines immunodefizienz-virus |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| CA2211743A1 (en) | 1995-02-21 | 1996-08-29 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
| JPH11503024A (ja) | 1995-04-04 | 1999-03-23 | セル・ジェネシス・インコーポレイテッド | 細胞表面のクラスｉ ｍｈｃタンパク質の低レベルを有する遺伝子学的に修飾された細胞の移植 |
| ATE288764T1 (de) | 1996-07-31 | 2005-02-15 | Ortho Mcneil Pharm Inc | Erkennung von menschlichen cytomegalovirus genes, welche die expression von mhc klasse i schweren ketten erniedrigen |
| US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| AU3910097A (en) | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
| US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
| CA2437201C (en) | 2001-02-02 | 2008-11-18 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| WO2002066629A2 (en) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
| AU2002362368B2 (en) | 2001-09-20 | 2006-09-21 | Glaxo Group Limited | HIV-gag codon-optimised DNA vaccines |
| US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
| US20060073123A1 (en) | 2002-04-30 | 2006-04-06 | Jie Mi | Adenovirus vectors for immunotherapy |
| DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
| US7407744B2 (en) | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
| US20080199493A1 (en) | 2004-05-25 | 2008-08-21 | Picker Louis J | Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors |
| EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
| US20080044384A1 (en) | 2004-06-25 | 2008-02-21 | Medlmmune Vaccines, Inc. | Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens |
| EP1888622A1 (en) | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
| US8765146B2 (en) | 2005-08-31 | 2014-07-01 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| WO2008112146A2 (en) | 2007-03-07 | 2008-09-18 | The Trustees Of The University Of Pennsylvania | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
| JP2010532764A (ja) | 2007-07-06 | 2010-10-14 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド |
| CA2703279C (en) | 2007-10-30 | 2014-04-22 | Genentech, Inc. | Antibody purification by cation exchange chromatography |
| JP2012519484A (ja) | 2009-03-06 | 2012-08-30 | マウント・シナイ・スクール・オヴ・メディシン | マイクロｒｎａ応答要素を含む弱毒化生インフルエンザウイルスワクチン |
| ES2786039T3 (es) | 2009-04-30 | 2020-10-08 | Ospedale San Raffaele Srl | Vector génico |
| KR20120105543A (ko) | 2009-12-23 | 2012-09-25 | 4-안티바디 아게 | 인간 사이토메갈로바이러스에 대한 결합 멤버 |
| EP2529227B1 (en) | 2010-01-27 | 2015-10-07 | Oregon Health & Science University | Cytomegalovirus-based immunogenic preparations |
| AU2011230619C1 (en) | 2010-03-25 | 2016-06-23 | Oregon Health & Science University | CMV glycoproteins and recombinant vectors |
| ES2679245T3 (es) | 2010-05-05 | 2018-08-23 | Sirion Biotech Gmbh | Vacuna contra la infección por beta-herpesvirus y uso de la misma |
| SI3333265T1 (sl) * | 2010-05-14 | 2020-08-31 | Oregon Health & Science University | Rekombinantni HCMV in RHCMV vektorji, ki kodirajo heterologni antigen izoliran iz virusa hepatitisa B virus in njihove uporabe |
| LT2691530T (lt) | 2011-06-10 | 2018-08-10 | Oregon Health & Science University | Cmv glikoproteinai ir rekombinantiniai vektoriai |
| US20140227708A1 (en) | 2011-09-16 | 2014-08-14 | Oregon Health & Science University | Methods and kits used in identifying microrna targets |
| US20130156808A1 (en) | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| US20150307850A1 (en) | 2012-12-04 | 2015-10-29 | Merck Sharp & Dohme Corp. | Conditional replicating viral vectors |
| HRP20181930T1 (hr) | 2013-03-05 | 2019-01-11 | Oregon Health & Science University | Citomegalovirus vektori za kontroliranje ciljanja t-stanica |
| CN107002048B (zh) | 2014-07-16 | 2021-07-06 | 俄勒冈健康与科学大学 | 包含外源抗原的人巨细胞病毒 |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| CA2976245A1 (en) | 2015-02-10 | 2016-08-18 | Oregon Health & Science University | Methods and compositions useful in generating non canonical cd8+ t cell responses |
| US10688164B2 (en) | 2015-11-20 | 2020-06-23 | Oregon Health & Science University | CMV vectors comprising microRNA recognition elements |
| EP3474889A4 (en) * | 2016-06-22 | 2020-04-29 | International AIDS Vaccine Initiative, Inc. | RECOMBINANT CYTOMEGALOVIRUS VECTORS FOR USE AS TUBERCULOSIS VACCINES |
| JP6987134B2 (ja) | 2016-06-27 | 2021-12-22 | ジュノー セラピューティクス インコーポレイテッド | ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途 |
| MX2019004518A (es) | 2016-10-18 | 2019-06-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que provocan celulas t restringidas por moleculas del complejo mayor de histocompatibilidad e. |
-
2017
- 2017-10-18 MX MX2019004518A patent/MX2019004518A/es unknown
- 2017-10-18 CN CN201780064422.7A patent/CN110036112B/zh active Active
- 2017-10-18 TN TNP/2019/000124A patent/TN2019000124A1/en unknown
- 2017-10-18 EP EP17862978.8A patent/EP3529363B1/en active Active
- 2017-10-18 SG SG11201903340TA patent/SG11201903340TA/en unknown
- 2017-10-18 US US15/786,847 patent/US10532099B2/en active Active
- 2017-10-18 JP JP2019520801A patent/JP2019531745A/ja active Pending
- 2017-10-18 KR KR1020197013148A patent/KR102604486B1/ko active Active
- 2017-10-18 WO PCT/US2017/057106 patent/WO2018075591A1/en not_active Ceased
- 2017-10-18 CR CR20190205A patent/CR20190205A/es unknown
- 2017-10-18 AU AU2017346788A patent/AU2017346788A1/en not_active Abandoned
- 2017-10-18 EA EA201990937A patent/EA201990937A1/ru unknown
- 2017-10-18 UA UAA201904893A patent/UA126860C2/uk unknown
- 2017-10-18 PE PE2019000824A patent/PE20190840A1/es unknown
- 2017-10-18 BR BR112019007982A patent/BR112019007982A2/pt not_active Application Discontinuation
- 2017-10-18 CA CA3040303A patent/CA3040303A1/en active Pending
- 2017-10-18 MA MA046588A patent/MA46588A/fr unknown
- 2017-10-18 IL IL266011A patent/IL266011B2/en unknown
-
2019
- 2019-04-08 DO DO2019000086A patent/DOP2019000086A/es unknown
- 2019-04-17 CL CL2019001054A patent/CL2019001054A1/es unknown
- 2019-04-24 CO CONC2019/0004102A patent/CO2019004102A2/es unknown
- 2019-05-07 EC ECSENADI201931754A patent/ECSP19031754A/es unknown
- 2019-11-26 US US16/696,403 patent/US11305015B2/en active Active
-
2022
- 2022-10-21 JP JP2022169043A patent/JP7478794B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531745A5 (enExample) | ||
| JP2019502371A5 (enExample) | ||
| JP7286796B2 (ja) | マイクロｒｎａ適合ｓｈｒｎａ（ｓｈｒｎａｍｉｒ）を含む遺伝子改変免疫細胞 | |
| Taki et al. | Tumor immune microenvironment during epithelial–mesenchymal transition | |
| Nishimura et al. | Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation | |
| Xiao et al. | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy | |
| Suehiro et al. | Clinical outcomes of a novel therapeutic vaccine with Tax peptide‐pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study | |
| CN104087592B (zh) | Afp158-166特异性tcr基因及其转基因t细胞及体外增殖方法及用途 | |
| Kamphorst et al. | CD4 T-cell immunotherapy for chronic viral infections and cancer | |
| KR102357004B1 (ko) | 입양 세포 면역요법의 효능을 강화하기 위한 조성물 및 방법 | |
| Abdul‐Wahid et al. | Induction of antigen‐specific TH9 immunity accompanied by mast cell activation blocks tumor cell engraftment | |
| CN110036112B (zh) | 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体 | |
| JP2017513472A5 (enExample) | ||
| Su et al. | Nasopharyngeal carcinoma and its microenvironment: past, current, and future perspectives | |
| JP2017508468A5 (enExample) | ||
| Redeker et al. | The quantity of autocrine IL-2 governs the expansion potential of CD8+ T cells | |
| Nishimura et al. | Cancer immunotherapy using novel tumor‐associated antigenic peptides identified by genome‐wide cDNA microarray analyses | |
| JP2017522312A5 (enExample) | ||
| Zhou et al. | Cancer vaccines: current status and future directions | |
| Ryan | microRNAs in cancer susceptibility | |
| RU2016139643A (ru) | Способ создания т-клеток, пригодных для аллогенной трансплантации | |
| JP2019508044A5 (enExample) | ||
| Sundarasetty et al. | Lentivirus-induced dendritic cells for immunization against high-risk WT1+ acute myeloid leukemia | |
| JP2018520669A5 (enExample) | ||
| Kim et al. | Recombinant Mycobacterium paragordonae expressing SARS-CoV-2 receptor-binding domain as a vaccine candidate against SARS-CoV-2 infections |